{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:19:14Z","timestamp":1790014754712,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.yebeh.2025.110426","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:11:49Z","timestamp":1745687509000},"page":"110426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Adjunctive use of cannabidiol in pediatric drug-resistant epilepsy: A retrospective multicenter analysis"],"prefix":"10.1016","volume":"169","author":[{"given":"Ermekbaeva","family":"Aizara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.Varughese","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbina Lopez","family":"Amy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milosh","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rebecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suri","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Yash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kothare","family":"Sanjeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110426_b0005","unstructured":"B\u00e9chard, P. and O.M. Ayala, Reducing hallucination in structured outputs via Retrieval-Augmented Generation. arXiv preprint arXiv:2404.08189, 2024."},{"key":"10.1016\/j.yebeh.2025.110426_b0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","article-title":"Cannabinoids in treatment-resistant epilepsy: a review","volume":"70","author":"O'Connell","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110426_b0015","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110426_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2025.110426_b0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2004.07.030","article-title":"Cannabinoid physiology and pharmacology: 30 years of progress","volume":"47","author":"Howlett","year":"2004","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110426_b0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.00049.2021","article-title":"Cannabinoid treatments in epilepsy and seizure disorders","volume":"104","author":"Devinsky","year":"2024","journal-title":"Physiol Rev"},{"key":"10.1016\/j.yebeh.2025.110426_b0035","unstructured":"FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. 2018 [cited 2024 13 October]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110426_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110426_b0045","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"10.1016\/j.yebeh.2025.110426_b0050","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"10125","key":"10.1016\/j.yebeh.2025.110426_b0055","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110426_b0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110426_b0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/can.2019.0082","article-title":"An open retrospective study of a standardized cannabidiol based-oil in treatment-resistant epilepsy","volume":"7","author":"Marchese","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.yebeh.2025.110426_b0070","series-title":"International Review of Neurobiology","first-page":"135","author":"Moreira","year":"2024"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110426_b0075","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110426_b0080","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"Patsalos","year":"2020","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110426_b0085","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110426_b0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110426_b0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yebeh.2018.01.026","article-title":"Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center","volume":"80","author":"Porcari","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110426_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.braindev.2020.06.018","article-title":"Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist?","volume":"43","author":"Uliel-Sibony","year":"2021","journal-title":"Brain and Development"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110426_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1528-1157.1978.tb05011.x","article-title":"Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats","volume":"19","author":"Corcoran","year":"1978","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110426_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2009.06.007","article-title":"Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy","volume":"57","author":"Blair","year":"2009","journal-title":"Neuropharmacology"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:54:53Z","timestamp":1766152493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":22,"alternative-id":["S1525505025001659"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110426","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive use of cannabidiol in pediatric drug-resistant epilepsy: A retrospective multicenter analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110426"}}